Please login to the form below

Not currently logged in
Email:
Password:

breast cancer

This page shows the latest breast cancer news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

cancer. However, AZ has two other targeted drugs – PARP inhibitor Lynparza (olaparib) for breast and ovarian cancer and EGFR blocker Tagrisso (osimertinib) – still in the growth phase. ... Seattle Genetics/Takeda’ s classical Hodgkin lymphoma

Latest news

More from news
Approximately 95 fully matching, plus 679 partially matching documents found.

Latest Intelligence

  • 30 women leaders in UK healthcare (part 3) 30 women leaders in UK healthcare (part 3)

    policy campaigning and research, and putting breast cancer firmly on the public agenda. ... kind. Its stated ambition is that, by 2050, everyone who develops breast cancer will live.

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being

  • The tipping point The tipping point

    In 2016 alone, there were approximately 30 oncology drugs in late stage development for breast cancer, leukaemia, lung cancer and ovarian cancer.

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... Women could be denied access to a drug for incurable breast cancer, ’tweeted an oncology nurse.

  • Engaging the digital healthcare professional Engaging the digital healthcare professional

    When NICE, the UK policymaker for health spending, rejected Pfizer’s breast cancer drug palbociclib for routine funding on the NHS in February, it tweeted the news and invited comments on ... Breast Cancer Now is followed by almost 40, 000, and its

More from intelligence
Approximately 1 fully matching, plus 52 partially matching documents found.

Latest appointments

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    s cancer programme, associate director for strategic relations for the Duke Cancer Institute among other roles. ... cancer research, especially metastatic breast cancer, where she has led programmes that resulted in numerous ground-breaking regulatory

  • Ipsen boosts specialty care and R&D leadership teams Ipsen boosts specialty care and R&D leadership teams

    Prior to this, he served as executive director and breast cancer lead for US oncology medical affairs, and held a number of medical affairs oncology positions at Novartis and Bayer.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Agendia appoints chairman of medical advisory board Agendia appoints chairman of medical advisory board

    Dr Hortobagyi brings over 35 years of experience in clinical and translational research of breast cancer and work as a breast medical oncologist to the molecular cancer diagnostics company. ... He currently also serves as a professor and chair Emeritus

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Genetic counsellors: the new healthcare influencers?

    A 2017 study of more than 2, 500 women with stage-0 to stage-2 breast cancer, carried out by researchers at Stanford University School of Medicine, found physicians often failed ... to recommend genetic testing to high-risk breast cancer patients,

  • FALCON trial of fulvestrant for advanced breast cancer

    FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. ... In the interview, he explains that the study was designed to address the

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics